BPX 601Alternative Names: BPX601
Latest Information Update: 01 Mar 2017
At a glance
- Originator Bellicum Pharmaceuticals
- Class CAR-T cell therapies; Immunotherapies
- Mechanism of Action Immunostimulants; T lymphocyte stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase I Pancreatic cancer